PATHOPHYSIOLOGY, RISK ASSESSMENT, AND MANAGEMENT FOR ASTHMA PATIENTS DURING THE COVID-19 PANDEMIC OUTBREAK

Abstract

Innumerable personages are associated with susceptibility to the COVID-19 pandemic viral infection evolution, which has globally overblown the healthcare facilities. Following the emergence of respiratory syndrome coronavirus, 2019- nCoV delineates as a third major emergence of a novel coronavirus. β-coronavirus having suspected origin from bat comprehend congestion of the respiratory system, indicating a worldwide life threat to around 235 million asthma patients’ existents as per WHO records. This review aims to investigate the risk constituents involved in virus-induced asthma, its management and prevention, origin, and transmission of coronavirus, including the relationship between different CoV infections. This review culminated the role of cytokines and chemokines and others found in COVID19 patients, which could directly or indirectly affect the smooth muscle contractility reasoned to promote asthma severity, but this still remains unknown. The research highlights how essential it is to regularly wash your hands and clean surfaces that are touched by your hands in order to prevent illness. Some pre-clinical data suggests the preferred use of a PDE4 inhibitor like Roflumilast in case of uncontrolled virus-induced asthma exacerbations. Although there is a lack of particular asthma management so far, that is why the rectification of the consequences can only be done by taking supportive treatment.